Insights

As a practicing M&A attorney representing both strategic acquirers and venture-backed targets, I have had a front row seat to the...

President Trump’s shakeup of U.S. trade policy with its approach to tariffs is costing companies billions of dollars.

In a recent webinar hosted by the Licensing Executives Society, U.S. Patent and Trademark Office acting Director Coke Morgan Stewart...

The rise of President Trumps’ tariffs in 2025 has brought uncertainty to the profitability of product sales and has thrown a wrench in previously stable supply relationships.

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound).

Pursuant to 42 U.S.C. § 4081(a),[1] the Federal Emergency Management Agency (FEMA) is authorized to engage private insurers to sell...

Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term...

Foley & Lardner recently celebrated the four-year anniversary of our national partnership with Boys & Girls Clubs of America (BGCA),...

On August 6, the Virginia Bureau of Insurance (BOI) issued Administrative Letter 2025-03 (the Letter)[1] to all companies seeking to be...